Teva earmarks $1B for India

Here's more evidence that the developing world is hot, hot, hot. Teva Pharmaceutical Industries plans to invest a whopping $1 billion in India. The generics giant will spend between a quarter and a third of that on new manufacturing plants. The rest will go into acquisitions.

Teva recently bought 100 acres in Madhya Pradesh for new active pharmaceutical ingredient facilities. And banking sources told the Business Standard that Teva has been chasing major acquisitions on the subcontinent for three years. Possible targets: Indian drug makers Cipla, Aurobindo, Matrix, and Orchid.

"Teva considers India an interesting geographical region," a company spokeswoman told the local newspaper, "and is looking to broaden its activities in the country." Indeed.

- get the article in the Business Standard
- read this Pharmalot item

Suggested Articles

The cleaning procedures are so poor at a Zydus Cadila plant in India that the FDA says a sampling found 10 different cross-contaminated products.

Oklahoma politicians contend J&J should be on the line for future abatement costs even after a $572 million verdict, but J&J sees things differently.

Abbott helmsman Miles White, who oversaw the spinoffs of AbbVie and Hospira, will step down as CEO after 21 years at the top job.